Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

• Status: Not yet recruiting
• Trial end date: 2023-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori (H. pylori) infection is a common global infectious disease of the gastrointestinal tract. Helicobacter pylori eradication can effectively prevent the development of stomach cancer. Progressive application of dual therapy for the eradication of Helicobacter pylori. Tegoprazan, a Potassium-Competitive Acid Blockers. The efficacy of P-CAB agents represented by vonoprazan in H. pylori eradication therapy has been widely verified.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yanqing Li
• Collaborators: Linyi People's Hospital; The Affiliated Hospital of Qingdao University; The People's Hospital of Jimo; Weifang Medical University; Yuncheng Traditional Chinese Medicine Hospital; Zhengzhou Central Hospital
• Treatments: Amoxicillin; Esomeprazole

Criteria

Inclusion Criteria:

• Helicobacter pylori infection (either positive for histopathological test, rapid urease test, or C13/C14 urea breath test).

• Patients who have not previously received helicobacter pylori eradication therapy.

Exclusion Criteria:

• Serious underlying diseases, such as liver insufficiency, renal insufficiency, immunosuppression, malignant tumor, coronary heart disease (angina pectoris or coronary artery stenosis ≥ 75%).

• Those who are not willing to take contraceptive measures during pregnancy, lactation or the trial.

• Active gastrointestinal bleeding.

• History of drug allergy.

• History of upper gastrointestinal surgery.

• Medication history of bismuth, antibiotics and PPI within 4 weeks.

• Other behaviors that may increase the risk, such as alcohol and drug abuse.

• Unable or unwilling to provide informed consent.